LANNETT CO INC (LCI) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:LCI • US5160122009

0.6855 USD
+0.03 (+3.86%)
Last: Apr 19, 2023, 08:06 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to LCI. LCI was compared to 191 industry peers in the Pharmaceuticals industry. LCI may be in some trouble as it scores bad on both profitability and health. LCI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year LCI has reported negative net income.
  • LCI had a negative operating cash flow in the past year.
LCI Yearly Net Income VS EBIT VS OCF VS FCFLCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M -200M -300M

1.2 Ratios

  • LCI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LCI Yearly ROA, ROE, ROICLCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 1K

1.3 Margins

  • With a Gross Margin value of 12.26%, LCI perfoms like the industry average, outperforming 52.97% of the companies in the same industry.
  • In the last couple of years the Gross Margin of LCI has declined.
  • LCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
LCI Yearly Profit, Operating, Gross MarginsLCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

  • LCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for LCI has been increased compared to 1 year ago.
  • LCI has a worse debt/assets ratio than last year.
LCI Yearly Shares OutstandingLCI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LCI Yearly Total Debt VS Total AssetsLCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of -1.51, we must say that LCI is in the distress zone and has some risk of bankruptcy.
  • LCI's Altman-Z score of -1.51 is in line compared to the rest of the industry. LCI outperforms 45.66% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.51
ROIC/WACCN/A
WACC4.16%
LCI Yearly LT Debt VS Equity VS FCFLCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • LCI has a Current Ratio of 2.23. This indicates that LCI is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.23, LCI is doing worse than 63.01% of the companies in the same industry.
  • LCI has a Quick Ratio of 1.39. This is a normal value and indicates that LCI is financially healthy and should not expect problems in meeting its short term obligations.
  • LCI has a worse Quick ratio (1.39) than 68.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.23
Quick Ratio 1.39
LCI Yearly Current Assets VS Current LiabilitesLCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for LCI have decreased strongly by -129.18% in the last year.
  • The Revenue for LCI has decreased by -24.09% in the past year. This is quite bad
  • The Revenue for LCI have been decreasing by -11.78% on average. This is quite bad
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%

3.2 Future

  • LCI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.51% yearly.
  • The Revenue is expected to decrease by -0.68% on average over the next years.
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LCI Yearly Revenue VS EstimatesLCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
LCI Yearly EPS VS EstimatesLCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LCI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LCI Price Earnings VS Forward Price EarningsLCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LCI Per share dataLCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.42%
EPS Next 3Y8.51%

More info and screens

0

5. Dividend

5.1 Amount

  • LCI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LANNETT CO INC

NYSE:LCI (4/19/2023, 8:06:04 PM)

0.6855

+0.03 (+3.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-01
Earnings (Next)05-02
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners133.44%
Ins Owner Change0%
Market Cap7.38M
Revenue(TTM)308.52M
Net Income(TTM)-192.52M
Analysts46.67
Price Target4.08 (495.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.25%
Min EPS beat(2)8.61%
Max EPS beat(2)17.89%
EPS beat(4)4
Avg EPS beat(4)9.07%
Min EPS beat(4)4.48%
Max EPS beat(4)17.89%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)9.34%
Min Revenue beat(2)8.96%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)2.45%
Min Revenue beat(4)-7.25%
Max Revenue beat(4)9.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)300%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-294.94%
EPS NY rev (1m)0%
EPS NY rev (3m)-283.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.44
EYN/A
EPS(NY)-5.49
Fwd EYN/A
FCF(TTM)-5.56
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS28.66
BVpS-29
TBVpS-31.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.26%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.01%
GM growth 5Y-27.28%
F-Score2
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.23
Quick Ratio 1.39
Altman-Z -1.51
F-Score2
WACC4.16%
ROIC/WACCN/A
Cap/Depr(3y)48.49%
Cap/Depr(5y)64.83%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.82%
EPS Next Y-3.01%
EPS Next 2Y4.42%
EPS Next 3Y8.51%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.09%
Revenue growth 3Y-19.6%
Revenue growth 5Y-11.78%
Sales Q2Q%-6.49%
Revenue Next Year-11.78%
Revenue Next 2Y-5.15%
Revenue Next 3Y-0.68%
Revenue Next 5YN/A
EBIT growth 1Y-129.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year101.64%
EBIT Next 3Y40.89%
EBIT Next 5YN/A
FCF growth 1Y-354.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.84%
OCF growth 3YN/A
OCF growth 5YN/A

LANNETT CO INC / LCI FAQ

Can you provide the ChartMill fundamental rating for LANNETT CO INC?

ChartMill assigns a fundamental rating of 1 / 10 to LCI.


What is the valuation status for LCI stock?

ChartMill assigns a valuation rating of 0 / 10 to LANNETT CO INC (LCI). This can be considered as Overvalued.


Can you provide the profitability details for LANNETT CO INC?

LANNETT CO INC (LCI) has a profitability rating of 0 / 10.


Can you provide the financial health for LCI stock?

The financial health rating of LANNETT CO INC (LCI) is 2 / 10.